The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

Claims 1-20 (Canceled).

Claim 21 (Currently amended) A compound having the formula: ~~The compound of claim 1~~



wherein,

~~Each~~ R^1 is ~~independently~~



;

wherein

R^{19} is independently H or C1-C6 alkyl;

R^2 is $-NHR^3$, $-NHR^5$, $-NHR^6$, $-NR^5R^5$ or $-NR^5R^6$;

R^3 is independently aryl, phenyl optionally substituted with 1-5 independent R^4 on each ring, or heteroaryl optionally substituted with 1-4 independent R^4 on each ring;

R^4 is independently selected from H, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4-C10 cycloalkenyl, aryl, R^8, halo, CF_3, SR^5, OR^5, $OC(O)R^5$, NR^5R^5, NR^5R^6, NR^5R^{16}, $COOR^5$, NO_2, CN, $C(O)R^5$, $C(O)C(O)R^5$, $C(O)NR^5R^5$, $S(O)_nR^5$, $S(O)_nNR^5R^5$, $NR^5C(O)NR^5R^5$, $NR^5C(O)C(O)R^5$, $NR^5C(O)R^5$, $NR^5(COOR^5)$, $NR^5C(O)R^8$, $NR^5S(O)_nNR^5R^5$, $NR^5S(O)_nR^5$, $NR^5S(O)_nR^8$, $NR^5C(O)C(O)NR^5R^5$, $NR^5C(O)C(O)NR^5R^6$, $OC(O)NR^5R^5$, $OS(O)_nNR^5R^5$, $NR^5S(O)_nOR^5$, $P(O)(OR^5)_2$,

C1-C10 alkyl substituted with 1-3 independent

aryl, R^7 or R^8, or

C2-C10 alkenyl substituted with 1-3 independent aryl, R^7 or R^8;

n is independently 1 or 2;

R^5 is independently H, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4-C10 cycloalkenyl, aryl, R^9, haloalkyl,

C1-C10 alkyl substituted with 1-3 independent aryl, R^7 or R^9 groups,

C3-C10 cycloalkyl substituted with 1-3 independent aryl, R^7 or R^9 groups, or

C2-C10 alkenyl substituted with 1-3 independent aryl, R^7 or R^9,

R^6 is independently $C(O)R^5$, $COOR^5$, $C(O)NR^5R^5$, $C(=NR^5)NR^5R^5$, or $S(O)_n R^5$;

R^7 is independently halo, CF_3, SR^{10}, OR^{10}, $OC(O)R^{10}$, $NR^{10}R^{10}$, $NR^{10}R^{11}$, $NR^{11}R^{11}$, $COOR^{10}$, NO_2, CN, $C(O)R^{10}$, $OC(O)NR^{10}R^{10}$, $C(O)NR^{10}R^{10}$, $N(R^{10})C(O)R^{10}$, $N(R^{10})$ $(COOR^{10})$, $S(O)_n NR^{10}R^{10}$, $NR^{10}S(O)_n NR^{10}R^{10}$, $NR^{10}S(O)_n R^{10}$ or $P(O)(OR^5)_2$;

R^8 is independently a 3-8 membered monocyclic, 7-12 membered bicyclic, or 11-14 membered tricyclic ring system having 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms independently selected from O, N, or S, which may be saturated or unsaturated, and wherein 0, 1, 2, 3 or 4 atoms of each ring may be substituted by a substituent independently selected from C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4-C10 cycloalkenyl, aryl, R^9, halo, sulfur, oxygen, CF_3, SR^5, OR^5, $OC(O)R^5$, NR^5R^5, NR^5R^6, NR^6R^6, $COOR^5$, NO_2, CN, $C(O)R^5$, $C(O)NR^5R^5$, $S(O)_n NR^5R^5$, $NR^5C(O)NR^5R^5$, $NR^5C(O)R^9$, $NR^5S(O)_n NR^5R^5$, $NR^5S(O)_n R^9$,

C1-C10 alkyl substituted with 1-3 independent R^7, R^9 or aryl, or

C2-C10 alkenyl substituted with 1-3 independent R^7, R^9 or aryl;

R^9 is independently a 3-8 membered monocyclic, 7-12 membered bicyclic, or 11-14 membered tricyclic ring system having 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms independently selected

from O, N, or S, which may be saturated or unsaturated, and wherein 0, 1, 2 or 3 atoms of each ring may be substituted by a substituent independently selected from C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4-C10 cycloalkenyl, halo, sulfur, oxygen, CF_3, SR^{10}, OR^{10}, $NR^{10}R^{10}$, $NR^{10}R^{11}$, $NR^{11}R^{11}$, $COOR^{10}$, NO_2, CN, $C(O)R^{10}$, $S(O)_nR^{10}$, $S(O)_nNR^{10}R^{10}$ or $C(O)NR^{10}R^{10}$;

R^{10} is independently H, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4-C10 cycloalkenyl, haloalkyl,

C1-C10 alkyl optionally substituted with 1-3 independent substituents selected from C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4-C10 cycloalkenyl, halo, CF_3, OR^{12}, SR^{12}, $NR^{12}R^{12}$, $COOR^{12}$, NO_2, CN, $C(O)R^{12}$, $C(O)NR^{12}R^{12}$, $NR^{12}C(O)R^{12}$, $N(R^{12})(COOR^{12})$, $S(O)_nNR^{12}R^{12}$ or $OC(O)R^{12}$, or

phenyl optionally substituted with 1-3 independent substituents selected from C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4-C10 cycloalkenyl, halo, CF_3, OR^{12}, SR^{12}, $NR^{12}R^{12}$, $COOR^{12}$, NO_2, CN, $C(O)R^{12}$, $C(O)NR^{12}R^{12}$, $NR^{12}C(O)R^{12}$, $N(R^{12})(COOR^{12})$, $S(O)_nNR^{12}R^{12}$ or $OC(O)R^{12}$;

R^{11} is independently $C(O)R^{10}$, $COOR^{10}$, $C(O)NR^{10}R^{10}$ or $S(O)_nR^{10}$;

R^{12} is independently H, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4-C10 cycloalkenyl,

C1-C10 alkyl substituted with 1-3 independent substituents selected from C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4-C10 cycloalkenyl, halo, CF_3, OR^{13}, SR^{13}, $NR^{13}R^{13}$, $COOR^{13}$, NO_2, CN, $C(O)R^{13}$, $C(O)NR^{13}R^{13}$, $NR^{13}C(O)R^{13}$ or $OC(O)R^{13}$, or

phenyl optionally substituted with 1-3 independent substituents selected from C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4-C10 cycloalkenyl, halo, CF_3, OR^{13}, SR^{13}, $NR^{13}R^{13}$, $COOR^{13}$, NO_2, CN, $C(O)R^{13}$, $C(O)NR^{13}R^{13}$, $NR^{13}C(O)R^{13}$ or $OC(O)R^{13}$;

R^{13} is independently H, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4-C10 cycloalkenyl,

C1-C10 alkyl optionally substituted with halo, CF_3, OR^{14}, SR^{14}, $NR^{14}R^{14}$, $COOR^{14}$, NO_2 or CN, or

phenyl optionally substituted with halo, CF_3, OR^{14}, SR^{14}, $NR^{14}R^{14}$, $COOR^{14}$, NO_2 or CN;

R^{14} is independently H, C1-C10 alkyl, C3-C10 cycloalkyl or phenyl;

R^{16} is independently H, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4-C10 cycloalkenyl, aryl, R^8, halo, CF_3, $COOR^5$, $C(O)R^5$, $C(O)C(O)R^5$, $C(O)NR^5R^5$, $S(O)_nR^5$; $S(O)_nNR^5R^5$,

C1-C10 alkyl substituted with 1-3 independent aryl, R^7 or R^8, or

phenyl optionally substituted with substituted with 1-4 independent R^{23}, or

C2-C10 alkenyl substituted with 1-3 independent aryl, R^7 or R^8; and

R^{23} is independently selected from H, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4-C10 cycloalkenyl, aryl, R^8, halo, CF_3, SR^5, OR^5, $OC(O)R^5$, NR^5R^5, NR^5R^6, $COOR^5$, NO_2, CN, $C(O)R^5$, $C(O)C(O)R^5$, $C(O)NR^5R^5$, $S(O)_nR^5$; $S(O)_nNR^5R^5$, $NR^5C(O)NR^5R^5$, $NR^5C(O)C(O)R^5$, $NR^5C(O)R^5$, $NR^5(COOR^5)$, $NR^5C(O)R^8$, $NR^5S(O)_nNR^5R^5$, $NR^5S(O)_nR^5$, $NR^5S(O)_nR^8$, $NR^5C(O)C(O)NR^5R^5$, $NR^5C(O)C(O)NR^5R^6$, $OC(O)NR^5R^5$, $OS(O)_nNR^5R^5$, $NR^5S(O)_nOR^5$, $P(O)(OR^5)_2$,

C1-C10 alkyl substituted with 1-3 independent aryl, R^7 or R^8, or

C2-C10 alkenyl substituted with 1-3 independent aryl, R^7 or R^8.

Claim 22 (Currently amended): A composition comprising a compound of any of claims ~~1~~—21 and 32 and a pharmaceutically acceptable carrier.

Claim 23 (Original): The composition of claim 22, further comprising at least one additional therapeutic agent.

Claims 24-26 (Canceled).

Claim 27 (Currently amended): A method of inhibiting angiogenesis or vasculogenesis activity in a mammal comprising

administration of a composition comprising an effective amount of a compound of any of claims ~~1~~—21 and 32.

Claim 28 (Currently amended): A method of making a pharmaceutically useful composition comprising combining an effective amount of a compound of any of claims ~~1~~—21 and 32 with one or more pharmaceutically acceptable carriers.

Claim 29 (Currently amended): The method of claim 28, further comprising combining an effective amount of an additional therapeutic agent.

Claim 30-31 (Canceled).

Claim 32 (New): Compound of Claim 22 and a pharmaceutically acceptable salt thereof selected from











































































































































































































































and



Claims 1, 6 and 22 were rejected under 35 USC §102(b) as being anticipated by Cutler et al. US 3,209,003. Applicants request reconsideration of the rejection in view of the amended Claims.

Claim 1 was rejected under 35 USC §102(b) as being anticipated by Fischer US 3,855,220. Applicants request reconsideration of the rejection in view of the amended Claims.

Claims 1, 6 and 22 were rejected under 35 USC §102(b) as being anticipated by Cutler et al. US 3,136,816. Applicants request reconsideration of the rejection in view of the amended Claims.

Claims 1, 6 and 22 were rejected under 35 USC §102(b) as being anticipated by Thurston US 2,474,194. Applicants request reconsideration of the rejection in view of the amended Claims.

Claims 1, 6, 8-9 and 30-31 were rejected under 35 USC §103(a) as being unpatentable over Newton et al. US 5,062,882. Newton describes tri-substituted triazines as herbicides (weed killers). There is no teaching as to the desirability of these compounds as pharmaceuticals, much less as kinase inhibitors. The pattern of preferences established by this reference also teaches away from the pyrazol-5-yl-amine substituted compounds of the current invention. The biological data described in Table 3 indicates that there was a substantial decrease in activity when R^1 is not methoxy (Examples 8-11). Therefore, assuming a medicinal chemist would look at herbicidal art, they would be taught away form the compounds of the present invention. Applicants contend that Newton et al. do not render obvious the pyrazol-5-yl-amine substituted triazines of the present invention.

Claims 1, 6 and 30-31 were rejected under 35 USC §103(a) as being unpatentable over Riebel et al. US 6,284,710 (the "'710" patent). Riebel et al. describe triazines as herbicides (weed killers). There is no teaching as to the desirability of these compounds as pharmaceuticals, much less as kinase inhibitors. In addition, the pre-emergent and post-emergent "spray and pray" test results provided in Tables A-B teach one skilled in agricultural chemistry away from the present invention. Examples 7, 11 and 52 were the only compounds that didn't kill every plant species (both crop and weed). This indicates that the "Z-substituent" was important for controlling non-